Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

RANGE trial of ramucirumab for urothelial cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.09.17
Views: 1598

Prof Daniel Petrylak - Yale Cancer Center, New Haven, Connecticut, USA

Prof Petrylak speaks with ecancer at ESMO 2017 about the combination of docetaxel and ramucirumab, a targeted therapy against VEGFR2, to treat metastatic urothelial carcinoma.

He describes the angiogenic control of the added antibody leading to a doubled progression free survival and overall response rate, with a trend towards improved overall survival, though notes this was not what the trial was powered for.

Prof Petrylak describes the toxicity of the combination as well tolerated, and that this is a suitable treatment choice for urothelial cancer patients.

Watch Prof Petrylak present these results at a press conference here, and read more in our press coverage here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

CML Life Banner

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation